NCT06563817View on ClinicalTrials.gov

The Safety and Efficacy of Rapamycin on Communicating Hydrocephalus Secondary to Intraventricular Hemorrhage

PHASE2RecruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

August 31, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

July 31, 2025

Conditions
Communicating HydrocephalusCerebral Intraventricular HemorrhageSecondary Normal Pressure HydrocephalusPost Hemorrhagic Hydrocephalus
Interventions
DRUG

Rapamycin

All enrolled patients receive treatment with sirolimus (rapamycin)#The prescribed regimen involved a daily oral dosage of 1.5 mg for a duration of four weeks.

Trial Locations (1)

100070

RECRUITING

Beijing Tiantan Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Tiantan Hospital

OTHER